These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 26293563)

  • 1. Testing times ahead.
    Goodrick S
    Lancet Neurol; 2015 Sep; 14(9):879. PubMed ID: 26293563
    [No Abstract]   [Full Text] [Related]  

  • 2. 2013 FDA drug approvals.
    Mullard A
    Nat Rev Drug Discov; 2014 Feb; 13(2):85-9. PubMed ID: 24481294
    [No Abstract]   [Full Text] [Related]  

  • 3. Regulatory watch: FDA guidance on co-developing investigational drugs.
    Nat Rev Drug Discov; 2011 Feb; 10(2):86. PubMed ID: 21283094
    [No Abstract]   [Full Text] [Related]  

  • 4. GAIN Act legislation: is it enough?
    Tillotson GS
    Lancet Infect Dis; 2012 Nov; 12(11):823-4. PubMed ID: 23099071
    [No Abstract]   [Full Text] [Related]  

  • 5. Health, Wealth, and the 21st Century Cures Act.
    Lo AW; Philipson TJ; von Eschenbach AC
    JAMA Oncol; 2016 Jan; 2(1):17-8. PubMed ID: 26513279
    [No Abstract]   [Full Text] [Related]  

  • 6. Regulatory watch: Outcomes of EMA marketing authorization applications: does partnering have an influence?
    van den Bogert CA; Souverein PC; Putzeist M; Leufkens HG; Janssen SW; Koëter GH
    Nat Rev Drug Discov; 2014 Dec; 13(12):878. PubMed ID: 25394870
    [No Abstract]   [Full Text] [Related]  

  • 7. Is the priority review voucher program stimulating new drug development for tropical diseases?
    Kerr KW; Henry TC; Miller KL
    PLoS Negl Trop Dis; 2018 Aug; 12(8):e0006695. PubMed ID: 30092022
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improving the FDA's advisory committee process.
    Brass EP; Hiatt WR
    J Clin Pharmacol; 2012 Aug; 52(8):1277-83. PubMed ID: 21908879
    [No Abstract]   [Full Text] [Related]  

  • 9. Target small firms for antibiotic innovation.
    Hwang TJ; Carpenter D; Kesselheim AS
    Science; 2014 May; 344(6187):967-9. PubMed ID: 24876477
    [No Abstract]   [Full Text] [Related]  

  • 10. Raising the bar for market authorisation of new drugs.
    Naci H; Cylus J; Vandoros S; Sato A; Perampaladas K
    BMJ; 2012 Aug; 345():e4261. PubMed ID: 22872693
    [No Abstract]   [Full Text] [Related]  

  • 11. Drug development for neglected diseases - the trouble with FDA review vouchers.
    Kesselheim AS
    N Engl J Med; 2008 Nov; 359(19):1981-3. PubMed ID: 18987367
    [No Abstract]   [Full Text] [Related]  

  • 12. The complexity of integrating speed and safety in drug development and approval.
    Charo RA
    JAMA Intern Med; 2013 Jul; 173(13):1165-6. PubMed ID: 23568604
    [No Abstract]   [Full Text] [Related]  

  • 13. The terminally ill, access to investigational drugs, and FDA rules.
    Blake V
    Virtual Mentor; 2013 Aug; 15(8):687-91. PubMed ID: 23937785
    [No Abstract]   [Full Text] [Related]  

  • 14. Botanicals as "new" drugs: US development.
    Hoffman FA
    Epilepsy Behav; 2015 Nov; 52(Pt B):338-43. PubMed ID: 26319115
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The 21st Century Cures Act--Will It Take Us Back in Time?
    Avorn J; Kesselheim AS
    N Engl J Med; 2015 Jun; 372(26):2473-5. PubMed ID: 26039522
    [No Abstract]   [Full Text] [Related]  

  • 16. Drug development: current challenges and federal initiatives.
    Strawbridge S; Hobbs L
    Conn Med; 2014; 78(10):595-600. PubMed ID: 25745738
    [No Abstract]   [Full Text] [Related]  

  • 17. Regulating medicines.
    Drug Ther Bull; 2012 Dec; 50(12):133. PubMed ID: 23220256
    [No Abstract]   [Full Text] [Related]  

  • 18. Biosimilars: where we were and where we are.
    Challand R; Gorham H; Constant J
    J Biopharm Stat; 2014; 24(6):1154-64. PubMed ID: 25036475
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Industry and regulatory performance in 2012: a year in review.
    Dowden HM; Jahn R; Catka T; Jonsson A; Michael E; Miwa Y; Zinkand W
    Clin Pharmacol Ther; 2013 Sep; 94(3):359-66. PubMed ID: 23657160
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FDA not NIH can speed new drugs.
    Miller HI
    Nature; 2011 Apr; 472(7342):169. PubMed ID: 21490657
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.